Skip to content
Axcess News – Lifestyle
Author:
Annovis Bio Inc.
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026
Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026
May 7, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 29, 2026
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
April 9, 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist
March 31, 2026
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson’s Disease Study
March 19, 2026
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
March 16, 2026
1
2
Next Page
→